Search Results

You are looking at 1 - 8 of 8 items for :

  • "MALT lymphoma" x
  • Refine by Access: All x
Clear All
Full access

Gastric MALT Lymphoma Treated With Primary Radiotherapy in the Setting of Autoimmune Disease

Chelsea C. Pinnix, Valerie Reed, and Bouthaina Dabaja

cell, they are distinct diseases with unique clinicopathologic features. MALT lymphoma is the third most common NHL, representing roughly 8% of all cases. 1 It can arise in a variety of primary sites, including the stomach, ocular adnexa, salivary

Full access

Marginal Zone Lymphoma

Omid S. Shaye and Alexandra M. Levine

mucosa-associated lymphoid tissue B-cell lymphoma . J Clin Oncol 2001 ; 19 : 1600 – 1609 . 14. Ye H Liu H Attygalle A . Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA

Full access

Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment

Presented by: Stephen D. Smith

to apply ISRT can yield long-term remissions. Finally, chemoimmunotherapy is reserved for patients with advanced-stage disease or disseminated nodal involvement. Gastric MALT Lymphoma For patients with gastric MALT lymphoma and positive H pylori

Full access

Reassessing the Standard of Care in Indolent Lymphoma: A Clinical Update to Improve Clinical Practice

Mathias Rummel

include FL, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and marginal zone lymphoma (MZL), which includes mucosa-associated lymphoid tissue (MALT) lymphoma, splenic MZL, and nodal MZL. 1 Lymphoplasmacytic lymphoma, also termed

Full access

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Sven De Vos, Bhagirathbhai Dholaria, Bita Fakhri, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Francisco Hernandez-Ilizaliturri, Eric Hsi, Boyu Hu, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Megan Lim, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

, page 1220). Marginal Zone Lymphomas MZLs originate in the marginal zone of lymphoid follicles found in the mucosa-associated lymphoid tissues (MALT), spleen, and lymph nodes. Extranodal MZLs of MALT (MALT lymphomas), nodal MZL (NMZL), and

Full access

Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo

comorbidity index using physician claims data . J Clin Epidemiol 2000 ; 53 : 1258 – 1267 . 20. Olszewski AJ Castillo JJ . Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER

Full access

Non-Hodgkin’s Lymphomas

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, John C. Byrd, Myron S. Czuczman, Luis Fayad, Andres Forero, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Youn H. Kim, Ann S. LaCasce, Tariq I. Mughal, Auyporn Nademanee, Pierluigi Porcu, Oliver Press, Leonard Prosnitz, Nashitha Reddy, Mitchell R. Smith, Lubomir Sokol, Lode Swinnen, Julie M. Vose, William G. Wierda, Joachim Yahalom, and Furhan Yunus

follows: DLBCL, 31%; follicular lymphoma (FL), 22%; small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), 6%; mantle cell lymphoma (MCL), 6%; peripheral T-cell lymphoma (PTCL), 6%; and mucosa-associated lymphoid tissue (MALT) lymphoma, 5%. The

Full access

Non-Hodgkin's Lymphomas

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nashitha Reddy, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, William G. Wierda, Joachim Yahalom, and Nadeem Zafar

follows: DLBCL, 31%; follicular lymphoma (FL), 22%; small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), 6%; mantle cell lymphoma (MCL), 6%; peripheral T-cell lymphoma (PTCL), 6%; and mucosa-associated lymphoid tissue (MALT) lymphoma, 5%. The